Richard Solomon

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. doi request reprint Forced diuresis with the RenalGuard system: Impact on contrast induced acute kidney injury
    Richard Solomon
    University of Vermont College of Medicine, USA Fletcher Allen Health Care, USA Electronic address
    J Cardiol 63:9-13. 2014
  2. pmc Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease
    Feliciano A Serrano
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Thromb J 5:7. 2007
  3. pmc Preventing contrast-induced nephropathy: problems, challenges and future directions
    Richard Solomon
    University of Vermont College of Medicine, Burlington, VT 05405 0068, USA
    BMC Med 7:24. 2009
  4. doi request reprint Contrast-induced acute kidney injury (CIAKI)
    Richard Solomon
    Department of Medicine, University of Vermont School of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA
    Radiol Clin North Am 47:783-8, v. 2009
  5. ncbi request reprint Contrast-induced nephropathy: update with special emphasis on patients with diabetes
    Richard Solomon
    Fletcher Allen Health Care, University of Vermont School of Medicine, UHC 2309, 1 South Prospect Street, Burlington, VT 05401, USA
    Curr Diab Rep 7:454-8. 2007
  6. doi request reprint Defining acute kidney injury: what is the most appropriate metric?
    Richard Solomon
    Division of Nephrology and Hypertension, Fletcher Allen Health Care at the University of Vermont College of Medicine, VT, USA
    Nat Clin Pract Nephrol 4:208-15. 2008
  7. ncbi request reprint Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease
    Richard J Solomon
    Department of Renal Services, Fletcher Allen Health Care, University of Vermont, Burlington, VT 05401, USA
    Circulation 115:3189-96. 2007
  8. ncbi request reprint Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects
    Richard Solomon
    University of Vermont, Burlington, VT 05401, USA
    Invest Radiol 41:651-60. 2006
  9. ncbi request reprint The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients
    Richard Solomon
    Fletcher Allen Health Care, Burlington, Vermont, USA
    Kidney Int 68:2256-63. 2005
  10. pmc Contrast-induced nephropathy and long-term adverse events: cause and effect?
    Richard J Solomon
    Department of Renal Services, Fletcher Allen Health Care, Burlington, VT 05401, USA
    Clin J Am Soc Nephrol 4:1162-9. 2009

Detail Information

Publications14

  1. doi request reprint Forced diuresis with the RenalGuard system: Impact on contrast induced acute kidney injury
    Richard Solomon
    University of Vermont College of Medicine, USA Fletcher Allen Health Care, USA Electronic address
    J Cardiol 63:9-13. 2014
    ..In this review; the mechanism of protective action is reviewed. The trials of the RenalGuard device are reviewed and future uses of the device are discussed. ..
  2. pmc Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease
    Feliciano A Serrano
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Thromb J 5:7. 2007
    ..To determine whether expression of FcGammaRIIA impacts platelet reactivity we quantified its expression and platelet reactivity in 33 patients with ESRD who were undergoing hemodialysis...
  3. pmc Preventing contrast-induced nephropathy: problems, challenges and future directions
    Richard Solomon
    University of Vermont College of Medicine, Burlington, VT 05405 0068, USA
    BMC Med 7:24. 2009
    ..In this commentary, the pathogenesis and clinical relevance of contrast-induced nephropathy are reviewed. Prophylactic strategies are discussed with a focus on the use of meta-analysis of small single-center trials...
  4. doi request reprint Contrast-induced acute kidney injury (CIAKI)
    Richard Solomon
    Department of Medicine, University of Vermont School of Medicine, 1 South Prospect Street, Burlington, VT 05401, USA
    Radiol Clin North Am 47:783-8, v. 2009
    ..After discussion of the reported incidence of CIAKI, an approach to prevention is briefly reviewed...
  5. ncbi request reprint Contrast-induced nephropathy: update with special emphasis on patients with diabetes
    Richard Solomon
    Fletcher Allen Health Care, University of Vermont School of Medicine, UHC 2309, 1 South Prospect Street, Burlington, VT 05401, USA
    Curr Diab Rep 7:454-8. 2007
    ..There have been few new insights into pathogenesis; despite multiple strategies aimed at prophylaxis, very few have proven efficacious. This article reviews our current knowledge regarding CIN, with emphasis on patients with diabetes...
  6. doi request reprint Defining acute kidney injury: what is the most appropriate metric?
    Richard Solomon
    Division of Nephrology and Hypertension, Fletcher Allen Health Care at the University of Vermont College of Medicine, VT, USA
    Nat Clin Pract Nephrol 4:208-15. 2008
    ..In this article we discuss the limitations and pitfalls of using serum markers to define AKI, and offer some suggestions for the future...
  7. ncbi request reprint Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease
    Richard J Solomon
    Department of Renal Services, Fletcher Allen Health Care, University of Vermont, Burlington, VT 05401, USA
    Circulation 115:3189-96. 2007
    ..No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients...
  8. ncbi request reprint Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects
    Richard Solomon
    University of Vermont, Burlington, VT 05401, USA
    Invest Radiol 41:651-60. 2006
    ..Recent studies suggest differences in the incidence of contrast-induced nephropathy (CIN) among contrast media (CM)...
  9. ncbi request reprint The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients
    Richard Solomon
    Fletcher Allen Health Care, Burlington, Vermont, USA
    Kidney Int 68:2256-63. 2005
    ....
  10. pmc Contrast-induced nephropathy and long-term adverse events: cause and effect?
    Richard J Solomon
    Department of Renal Services, Fletcher Allen Health Care, Burlington, VT 05401, USA
    Clin J Am Soc Nephrol 4:1162-9. 2009
    ..The relationship of contrast-induced nephropathy (CIN) to long-term adverse events (AEs) is controversial. Although an association with AEs has been previously reported, it is unclear whether CIN is causally related to these AEs...
  11. pmc N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients
    Tariq Rehman
    Division of Nephrology, Fletcher Allen Health Care and University of Vermont, Burlington, Vermont, USA
    Clin J Am Soc Nephrol 3:1610-4. 2008
    ..This confounding effect of N-acetylcysteine on serum creatinine has not been rigorously tested, however, in a population at risk for CIN and following doses of NAC currently recommended for prophylaxis of CIN...
  12. doi request reprint Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  13. pmc A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease
    Wajeh Qunibi
    Department of Medicine, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    BMC Nephrol 12:9. 2011
    ..This trial was conducted to examine the efficacy and safety of calcium acetate in controlling serum phosphorus in pre-dialysis patients with CKD...
  14. ncbi request reprint Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis
    Atul Aggarwal
    Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
    Nephrol Dial Transplant 19:1559-63. 2004
    ..Because both haemodialysis and unfractionated heparin (UFH) can increase platelet reactivity, we compared platelet reactivity during haemodialysis when patients were anticoagulated with UFH or enoxaparin...